Twenty-one novelN,4-diphenylpyrimidin-2-amine derivatives have been synthesized as PI3Kγ selective inhibitors and compoundC8demonstrated the most potent inhibitory activity against PI3Kγ kinase.
series of 2-amino-9-aryl-7H-pyrrolo[2,3-d]pyrimidines were designed and synthesized to target focal adhesion kinase (FAK). A number of these pyrrolopyrimides exhibited low micromolar inhibitory activities against focal adhesion kinase, and their preliminary SAR was established via systematic chemical modifications. The 2-amino-9-aryl-7H-pyrrolo[2,3-d]pyrimidines represent a new class of kinase inhibitors
[EN] PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS<br/>[FR] COMPOSES DE PYRADAZINE UTILES COMME INHIBITEURS DE GSK-3
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004035588A1
公开(公告)日:2004-04-29
The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds according to formula (I) and methods of their use.
本发明通常涉及激酶抑制剂,如GSK3,更具体地涉及根据式(I)的融合吡啶并嘧啶化合物及其使用方法。
[EN] PYRAZOLOPARIDAZINE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLOPARIDAZINE
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2003051886A1
公开(公告)日:2003-06-26
Fused pyradazine derivatives, which are useful as CDK inhibitors are described herein. The described invention also includes methods of making such fused pyradazines derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use.